Management of Inappropriate Sinus Tachycardia

Initial Assessment and Diagnosis Confirmation

The American College of Cardiology recommends ruling out systemic causes, such as hyperthyroidism, pheochromocytoma, anemia, infection, dehydration, heart failure, and pulmonary embolism, before initiating treatment for inappropriate sinus tachycardia 1, 2
The American Heart Association suggests eliminating exogenous triggers, including caffeine, alcohol, nicotine, sympathomimetic drugs, and illicit stimulants, to help manage inappropriate sinus tachycardia 2
The American College of Cardiology advises excluding physical deconditioning and medications that may cause tachycardia, as well as distinguishing from postural orthostatic tachycardia syndrome (POTS) before considering any invasive therapy 3, 1
Diagnostic criteria for inappropriate sinus tachycardia can be confirmed with 24-hour Holter monitoring showing persistent daytime heart rate >100 bpm, mean 24-hour heart rate >90 bpm, excessive rate increase with minimal activity, and nocturnal normalization 1, 2

The American College of Cardiology recommends beta-blockers as first-line therapy for symptomatic inappropriate sinus tachycardia, despite limited randomized trial evidence 3, 1
The American Heart Association suggests that beta-blockers are particularly effective for tachycardia triggered by emotional stress and anxiety-related disorders, and that cardioselective beta-blockers (such as metoprolol) are preferred 4
The American College of Cardiology advises that non-dihydropyridine calcium channel blockers (verapamil or diltiazem) may be considered when beta-blockers are contraindicated or not tolerated, with evidence supporting their effectiveness being anecdotal but clinically relevant 3, 1, 2
The American College of Cardiology recommends that catheter ablation should be reserved exclusively for patients with intolerable symptoms refractory to all medical therapy, with an acute success rate of 76-100% but long-term success only 66% with high recurrence rates 3, 1, 2

The American College of Cardiology warns against overtreatment, as aggressive attempts to normalize heart rate can cause more harm than the condition itself, given the benign long-term prognosis 3, 2
The American Heart Association advises against premature ablation, emphasizing the importance of exhausting medical options before considering invasive therapy, especially in patients without truly intolerable symptoms 3, 2
The American College of Cardiology stresses the importance of distinguishing IST from POTS to avoid inappropriate ablation with poor outcomes, and systematically excluding secondary causes before labeling as IST 3, 1, 2

The American College of Cardiology recommends that beta-blockers remain first-line therapy for pregnant women with inappropriate sinus tachycardia, with cardioselective agents preferred, and that catheter ablation should only be considered in refractory cases, preferably after the first trimester, in experienced centers with maximal radiation protection and use of echocardiographic/electroanatomic mapping systems 4

The FDA label for bupropion does not require routine ECG monitoring when initiating standard antidepressant doses (150–300 mg daily), in contrast to agents such as dofetilide or sotalol that mandate inpatient ECG surveillance because of QT‑prolongation and torsades de pointes risk. 5

Obtaining a 12‑lead ECG before starting bupropion is recommended to document baseline QTc and QRS duration, thereby excluding pre‑existing conduction disease that could increase seizure risk and providing a reference point for interpreting subsequent Holter data. 5

Bupropion initiation should be delayed in patients with structural heart disease (e.g., left‑ventricular hypertrophy, myocardial ischemia, or reduced ejection fraction) because these conditions heighten the risk of arrhythmias when combined with drug‑induced tachycardia. [5][6]
Bupropion initiation should be delayed in patients taking other QT‑prolonging medications or who have a baseline QTc > 480 ms, as the sympathomimetic effect of bupropion could theoretically increase the risk of torsades de pointes in this vulnerable population. [5][6]